Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.63 |
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17740047 | 0.94 | SLC6A5 (0.71) | SLC6A5FAAHDNM1CASP2NAAA | |
| SCHEMBL3996566 | 0.94 | SLC6A5 (0.56) | SLC6A5FAAHDNM1CNR1CASP2 | |
| SCHEMBL16302656 | 0.89 | FAAH (0.63) | FAAHDNM1CNR1CASP2NAAA | |
| SCHEMBL12581483 | 0.88 | SLC6A5 (0.79) | SLC6A5FAAHDNM1CNR1CASP2 | |
| SCHEMBL13984980 | 0.88 | SLC6A5 (0.73) | SLC6A5FAAHDNM1CNR1CASP2 | |
| SCHEMBL18874653 | 0.88 | SLC6A5 (0.73) | SLC6A5FAAHDNM1CNR1CASP2 | |
| SCHEMBL10973820 | 0.88 | SLC6A5 (0.73) | SLC6A5FAAHDNM1CNR1CASP2 | |
| SCHEMBL23796509 | 0.86 | SLC6A5 (0.82) | SLC6A5FAAHDNM1CASP2NAAA | |
| SCHEMBL23729790 | 0.86 | SLC6A5 (0.82) | SLC6A5FAAHDNM1CASP2NAAA | |
| SCHEMBL24591641 | 0.86 | SLC6A5 (0.82) | SLC6A5FAAHDNM1CASP2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016071856-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS AG (CH) | 2016-05-12 | — | — | WO | disclosed |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD (IE) | 2015-02-26 | — | — | US | disclosed |
| EP-1432700-B1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, TIE1, TEK | SLC6A5 4496/4885FAAH 2089/4885DNM1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.